Lanell M. Peterson

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial”.

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

Annals of Oncology(2023)10.1016/j.annonc.2023.08.003

N/A

1.4DataRank · unranked

61 citations

L.D. Eli, Hans Wildiers, Sara A. Hurvitz, Ángel Guerrero‐Zotano, Nisha Unni +37 more

Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer

Breast Cancer Research(2023)10.1186/s13058-023-01722-4

N/A

0.727DataRank · unranked

14 citations

Lanell M. Peterson, Isaac Jenkins, Alena Novakova-Jiresova, Hannah M. Linden, Julie R. Gralow +6 more

Functional 4-D clustering for characterizing intratumor heterogeneity in dynamic imaging: evaluation in FDG PET as a prognostic biomarker for breast cancer

European Journal of Nuclear Medicine and Molecular Imaging(2021)10.1007/s00259-021-05265-8

N/A

0DataRank · unranked

15 citations

Varsha Viswanath, Austin R. Pantel, Lanell M. Peterson, Aimilia Gastounioti, Eric A. Cohen +5 more

Matched FES and FDG PET imaging in patients with hormone receptor-positive, HER2+ advanced breast cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.1042

N/A

0DataRank · unranked

1 citations

Lanell M. Peterson, David A. Mankoff, Mark Muzi, Delphine L. Chen, Shaveta Vinayak +4 more

Repeatability of 18F-FDG uptake in metastatic bone lesions of breast cancer patients and implications for accrual to clinical trials

Research Square(2024)10.21203/rs.3.rs-3818932/v1

N/A

0DataRank · unranked

1 citations

Lanell M. Peterson, Jennifer M. Specht, Daniel S. Hippe, Alena Novakova-Jiresova, Jean H. Lee +6 more

Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2-positive or HER2-negative metastatic breast cancer

Breast Cancer Research(2025)10.1186/s13058-025-01975-1

N/A

0DataRank · unranked

1 citations

Lanell M. Peterson, Jennifer M. Specht, David A. Mankoff, Mark Muzi, Delphine L. Chen +5 more